# Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00275132** · PHASE3 · COMPLETED · sponsor: **University College, London** · enrollment: 670 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** Matched placebo

## Key facts

- **NCT ID:** NCT00275132
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 670 (ACTUAL)
- **Last updated:** 2014-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275132, "Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00275132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*